Creative BioMart to Present at BPS 2025 Annual Meeting | February 15-19, 2025

Recombinant Human TNFRSF18 Protein

Cat.No. : TNFRSF18-661H
Product Overview : Recombinant human TNFRSF18 protein without tag was expressed in HEK293.
  • Specification
  • Gene Information
  • Related Products
  • Download
Description : This gene encodes a member of the TNF-receptor superfamily. The encoded receptor has been shown to have increased expression upon T-cell activation, and it is thought to play a key role in dominant immunological self-tolerance maintained by CD25(+)CD4(+) regulatory T cells. Knockout studies in mice also suggest the role of this receptor is in the regulation of CD3-driven T-cell activation and programmed cell death. Three alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.
Source : HEK293
Species : Human
Form : Lyophilized
Molecular Mass : 15.4 kDa
Protein length : 241
AA Sequence : MAQHGAMGAFRALCGLALLCALSLG QRPTGGPGCGPGRLLLGTGTDARCC RVHTTRCCRDYPGEECCSEWDCMCV QPEFHCGDPCCTTCRHHPCPPGQGV QSQGKFSFGFQCIDCASGTFSGGHE GHCKPWTDCTQFGFLTVFPGNKTHN AVCVPGSPPAEPLGWLTVVLLAVAA CVLLLTSAQLGLHIWQLRSQCMWPR ETQLLLEVPPSTEDARSCQFPEEER GERSAEEKGRLGDLWV
Purity : > 98%
Applications : WB; ELISA; FACS; FC
Stability : This bioreagent is stable at 4 centigrade (short-term) and -70 centigrade(long-term). After reconstitution, sample may be stored at 4 centigrade for 2-7 days and below -18 centigrade for future use.
Storage : At -20 centigrade.
Concentration : 1 mg/mL
Storage Buffer : PBS (pH 7.4-7.5). Sterile-filtered colorless solution.
Reconstitution : Reconstitute in sterile distilled H2O to no less than 100 μg/mL; dilute reconstituted stock further in other aqueous solutions if needed. Please review COA for lot-specific instructions. Final measurements should be determined by the end-user for optimal performance.
Gene Name : TNFRSF18 tumor necrosis factor receptor superfamily, member 18 [ Homo sapiens (human) ]
Official Symbol : TNFRSF18
Synonyms : TNFRSF18; tumor necrosis factor receptor superfamily, member 18; tumor necrosis factor receptor superfamily member 18; AITR; CD357; GITR; activation-inducible TNFR family receptor; glucocorticoid-induced TNFR-related protein; TNF receptor superfamily activation-inducible protein; GITR-D;
Gene ID : 8784
mRNA Refseq : NM_004195
Protein Refseq : NP_004186
MIM : 603905
UniProt ID : Q9Y5U5

Not For Human Consumption!

Inquiry

  • Reviews
  • Q&As

Customer Reviews (3)

Write a review
Reviews
12/20/2021

    This flexibility enables researchers like myself to tailor TNFRSF18 protein experiments to our unique needs, enhancing the reliability and relevance of the obtained results.

    03/05/2020

      Their commitment to delivering exceptional products and assisting with any challenges that may arise ensures a successful and rewarding experimental journey.

      10/01/2017

        The TNFRSF18 protein offered by the manufacturer is of exceptional quality, and it meets the rigorous standards necessary for my experimental needs.

        Q&As (5)

        Ask a question
        What are some current clinical trials involving TNFRSF18-targeted therapies in cancer treatment? 12/20/2022

        Clinical trials are investigating TNFRSF18 agonists, such as monoclonal antibodies, in combination with other cancer treatments in various cancer types.

        Are there any approved TNFRSF18-targeted therapies for cancer treatment? 06/29/2019

        As of my knowledge cutoff date in January 2022, there were no approved TNFRSF18-targeted therapies for cancer. However, this may have changed since then.

        Are there potential side effects associated with TNFRSF18-targeted therapies? 12/30/2018

        Side effects may include immune-related adverse events, similar to those seen with other immunotherapies, and can range from mild to severe.

        How can TNFRSF18-targeted therapies potentially improve cancer outcomes? 05/05/2018

        TNFRSF18-targeted therapies may enhance the body's immune response against cancer cells, leading to better tumor control and improved patient outcomes.

        Can TNFRSF18-targeted therapies be used in combination with other immunotherapies? 05/20/2016

        Yes, combination therapies involving TNFRSF18 agonists and other immunotherapies are under investigation to improve treatment efficacy.

        Ask a Question for All TNFRSF18 Products

        Required fields are marked with *

        My Review for All TNFRSF18 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2025 Creative BioMart. All Rights Reserved.

        Contact Us

        • /
        • Service lnquiry:

        Stay Updated on the Latest Bioscience Trends